Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Data from mid-stage trial of Eli Lilly's investigational anticancer compound suggests that the investigational targeted therapy may be useful in treating patients with the most common form of non-Hodgkin's lymphoma.
Subscribe to our email newsletter
The data presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta, Georgia, showed that the drug, enzastaurin, slowed the progression of diffuse large B-cell lymphoma (DLBCL) in several patients pretreated with chemotherapy.
The five-year survival rate of US patients with non-Hodgkin’s lymphoma is only 59% with standard therapies, according to the Lymphoma Research Foundation.
“The use of enzastaurin in relapsed diffuse large B-cell lymphoma is important for two reasons,” said Dr Margaret Shipp, director of Dana-Farber/Harvard Cancer Center’s lymphoma program and the senior investigator in the clinical trial. “One, it represents a rational inhibitor of an identified target and, two, several patients with aggressive chemo-insensitive disease have had prolonged responses to this single, oral agent.”
Enzastaurin inhibits the PKC-Beta, a protein that stimulates cell growth. An over expression of PKC-Beta was identified as being linked to poor outcomes for patients with DLBCL.
In addition, preclinical data indicate that enzastaurin may have additional effects on cutting off the tumor’s blood supply, increasing the natural death of tumor cells and reducing the cell’s ability to reproduce.